NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Short Interest Update

NeuBase Therapeutics, Inc. (NASDAQ:NBSE) was the target of a large growth in short interest in March. As of March 31st, there was short interest totalling 149,100 shares, a growth of 85.2% from the March 15th total of 80,500 shares. Approximately 4.9% of the shares of the stock are short sold. Based on an average daily volume of 233,400 shares, the short-interest ratio is currently 0.6 days.

NeuBase Therapeutics Stock Up 7.0 %

Shares of NeuBase Therapeutics stock traded up $0.03 during trading on Friday, hitting $0.44. 73,268 shares of the stock traded hands, compared to its average volume of 230,849. The stock has a market cap of $1.65 million, a price-to-earnings ratio of -0.06 and a beta of 0.83. The firm’s fifty day moving average is $0.73 and its 200-day moving average is $0.72. NeuBase Therapeutics has a 52 week low of $0.39 and a 52 week high of $5.40.

Hedge Funds Weigh In On NeuBase Therapeutics

Several institutional investors have recently modified their holdings of NBSE. First Manhattan Co. bought a new position in shares of NeuBase Therapeutics during the 1st quarter valued at about $26,000. Renaissance Technologies LLC increased its position in shares of NeuBase Therapeutics by 20.2% during the 3rd quarter. Renaissance Technologies LLC now owns 287,386 shares of the company’s stock valued at $114,000 after purchasing an additional 48,255 shares during the last quarter. State Street Corp increased its position in shares of NeuBase Therapeutics by 18.4% during the 1st quarter. State Street Corp now owns 68,687 shares of the company’s stock valued at $129,000 after purchasing an additional 10,674 shares during the last quarter. Royal Bank of Canada increased its position in shares of NeuBase Therapeutics by 64.3% during the 1st quarter. Royal Bank of Canada now owns 114,473 shares of the company’s stock valued at $215,000 after purchasing an additional 44,791 shares during the last quarter. Finally, Worth Venture Partners LLC increased its position in shares of NeuBase Therapeutics by 11.9% during the 1st quarter. Worth Venture Partners LLC now owns 256,553 shares of the company’s stock valued at $482,000 after purchasing an additional 27,300 shares during the last quarter. 12.37% of the stock is currently owned by institutional investors.

About NeuBase Therapeutics

NeuBase Therapeutics, Inc, a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications.